The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non–small cell lung cancer
Authors:
- 17 March 2010
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 41 (7) , 951-959
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Novel DNA mismatch-repair activity involving YB-1 in human mitochondriaDNA Repair, 2009
- Two distinct pathways of cell death triggered by oxidative damage to nuclear and mitochondrial DNAsThe EMBO Journal, 2008
- Stimulation of NEIL2-mediated Oxidized Base Excision Repair via YB-1 Interaction during Oxidative StressJournal of Biological Chemistry, 2007
- Lung Cancer in Never Smokers: A ReviewJournal of Clinical Oncology, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The pleiotropic functions of the Y‐box‐binding protein, YB‐1BioEssays, 2003
- Global cancer statistics in the year 2000The Lancet Oncology, 2001